Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial
May 02, 2017 16:40 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4th
May 01, 2017 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd
March 17, 2017 07:55 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 17, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial
March 16, 2017 07:15 ET
|
Proteon Therapeutics, Inc.
- Efficacy endpoints reordered and co-primary endpoints established -- Ongoing trial, if successful, expected to serve as single pivotal study for BLA submission - - Conference Call Scheduled for...
Satellite Healthcare Recognizes National Kidney Month with Educational Presentations at the Annual Dialysis Conference
March 09, 2017 09:00 ET
|
Satellite Healthcare
SAN JOSE, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Satellite Healthcare, a leading national not-for-profit dialysis care provider, today recognizes World Kidney Day and National Kidney Month by...
Proteon Therapeutics Announces Two Presentations at the American Society of Diagnostic and Interventional Nephrology Meeting
February 06, 2017 17:00 ET
|
Proteon Therapeutics, Inc.
Review results of PATENCY-1, the Phase 3 trial of investigational vonapanitase Data on impact of fistula outcomes on Medicare costs WALTHAM, Mass., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Proteon...
Proteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD
December 13, 2016 07:00 ET
|
Proteon Therapeutics, Inc.
- Trial Did Not Meet Primary Efficacy Endpoint - - Important Secondary and Tertiary Endpoint Data and Enrollment in Second Phase 3 Ongoing - - Conference Call Scheduled for 8:30 AM ET - WALTHAM,...
Proteon Therapeutics to Participate in Two Upcoming Investor Conferences
November 09, 2016 16:35 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Third Quarter 2016 Financial Results
November 07, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
CMS Five-Star Quality Rating System Identifies Satellite Healthcare as Leading 10 Largest Dialysis Providers in Percentage of Top-Rated Dialysis Centers
October 27, 2016 15:31 ET
|
Satellite Healthcare
SAN JOSE, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Satellite Healthcare today announced that it leads the industry with the highest percentage of top-rated dialysis centers among the 10 largest...